Biotech launches personalized cancer treatment website

Share this article:
Champions Biotechnology, a company offering personalized cancer data for patients and physicians, launched a new website:

The website details Champions' personalized treatment offerings for cancer patients and their physicians, including tumorgrafts, vaccines and expert oncology panels – all catering to individual cancer patients.   

“Champions offers a more precise approach to cancer treatment, because every patient's cancer is unique,” said Doug Burkett, president of Champions Biotechnology, in a statement. “In partnership with one's physician, Champions optimizes a given treatment plan's potential for success and maximizes the patient's most precious resource: time.”

The personalized tumorgraft, for example, uses a sample of the patient's living tumor in order to test treatment options “through simultaneous evaluation of the effectiveness of numerous anti-cancer drugs,” according to the statement. A spokesperson at Champions said that the company is currently developing several of its own oncology products, but also has partnered with other biotechs including Centocor, ImClone, Concordia Pharmaceuticals and Gradalis. Personalized vaccines utilize tumorgrafts to predict a patient's immune system response to a given treatment, according to the website.

Champions' services aren't currently covered under any health insurance plan, and the patient costs for a tumorgraft, vaccine or oncology panel are not released in the public domain, according to a spokesperson.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Judge blocks FDA bid to allow generic Precedex

Judge blocks FDA bid to allow generic Precedex

The US District Court for Maryland granted Hospira a temporary restraining order (TRO) against FDA, after the agency determined that potential generic competitors of the company's injectable sedation drug Precedex ...

GSK drug gets aplastic anemia indication

GSK drug gets aplastic anemia indication

Promacta was previously indicated for chronic immune thrombocytopenia.

Five things for Pharma Marketers to know: Wednesday, August 27

Five things for Pharma Marketers to know: Wednesday, ...

Allergan sets a shareholder voting date, Novo describes the types of acquisitions it will consider, and the AstraZeneca-Pfizer talks can now reopen.